Predicting Pathological Complete Response in Neoadjuvant Dual Blockade With Trastuzumab and Pertuzumab in HER2 Gene Amplified Breast Cancer

BackgroundDual-targeted therapy is the standard treatment for human epidermal growth factor receptor 2 (HER2)-positive breast cancer, and effective biomarkers to predict the response to neoadjuvant trastuzumab and pertuzumab treatment need further investigation. Here, we developed a predictive model...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Yi Xiao, Jiahan Ding, Dachang Ma, Sheng Chen, Xun Li, Keda Yu
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2022-05-01
Colecção:Frontiers in Immunology
Assuntos:
trastuzumab
pertuzumab
predictive model
neoadjuvant treatment
HER2-amplified breast cancer
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fimmu.2022.877825/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados